Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05527314
Other study ID # 2022-EA-1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 23, 2022
Est. completion date February 7, 2023

Study information

Verified date March 2023
Source Second Affiliated Hospital of Nanchang University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date February 7, 2023
Est. primary completion date February 6, 2023
Accepts healthy volunteers No
Gender All
Age group 3 Years to 8 Years
Eligibility Inclusion Criteria: 1. ASA ?-? 2. Aged 3-8 years, weight > 10 kg, sex was not limited; 3. Children were scheduled for selective ophthalmic surgery under general anesthesia, Exclusion Criteria: 1. Respiratory infection was present within 4 weeks before surgery. 2. Potential or presence of difficult airways, airway obstruction, sleep apnea, and other contraindications to general anesthesia. 3. The blood routine or blood biochemical indexes were obviously abnormal. 4. Allergy or hypersensitive reaction to test drug, including remimazolam, sevoflurane, and remifentanil. 5. Any child who has taken benzodiazepines in the last 3 months. 6. Unable to cooperate to complete the test, and the guardian refused to attend. 7. Other reasons that researchers hold it is not appropriate to participate in this trial.

Study Design


Intervention

Drug:
Remimazolam
Anesthesia was induced with Remimazolam 0.4-0.8 mg/kg (about 1 minute) by intravenous injection until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h until the end of surgery.
Sevoflurane
Anesthesia was induced with 8 % Sevoflorane by sevoflurane volatilization tank until the loss of consciousness (LoC), followed by 2 %-3 % Sevoflorane until the end of surgery.
Fentanyl
Anesthesia was induced with fentanyl 3-4 ug/kg by intravenous injection after the LoC.
Cisatracurium Besylate
Anesthesia was induced with cisatracurium besilate 0.1 mg/kg by intravenous injection after the LoC. And the cisatracurium besilate 0.02 mg/kg is allowed to add as appropriate during the operation.
Remifentanil
After the LoC, remifentanil 0.1~0.3 ug/kg/min inject intravenously until the end of surgery.

Locations

Country Name City State
China the Second Affiliated Hospital of Nanchang University, Nanchang University Nanchang Jiangxi

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital of Nanchang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence of emergence agitation The PAED scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score. PAED scale >12 at any time indicates presence of emergence agitation. Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes
Primary The incidence of emergence agitation The Watcha scale consists of four items and scores >2 at any time indicates presence of emergence agitation. Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes
Primary The incidence of emergence agitation The 5-point scale consists of five items. The scores =4 and lasts for more than 5 minutes indicate presence of emergence agitation. Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes
Secondary Systolic pressure "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward". Up to 5 hours including preoperative, intraoperative, and postoperative periods
Secondary Diastolic pressure "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward". Up to 5 hours including preoperative, intraoperative, and postoperative periods
Secondary Mean pressure "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward". Up to 5 hours including preoperative, intraoperative, and postoperative periods
Secondary Heart rate "30 minutes before induction", "immediately after intubation", "every 5 minutes after intubation until the child leaves the post-anesthesia care unit and returns to the ward". Up to 5 hours including preoperative, intraoperative, and postoperative periods
Secondary Recovery times The period from discontinuation of anesthetic drugs to the recovery of the child's self-consciousness and can respond correctly to external stimuli. Up to 30 minutes after operation
Secondary Delayed emergence Delayed emergence is defined as failure to shake hands and no significant response to nociceptive stimuli more than 30 minutes after surgery. Up to 30 minutes after operation
Secondary Postoperative Pain The FLACC scale consists of fIve items. Each item is scored 0-2 yielding a total between 0 and 10. The degree of pain increased directly with the total score. During the recovery from anesthesia.
Secondary Complication All the perioperative complications are recorded. During the perioperative period
See also
  Status Clinical Trial Phase
Recruiting NCT06063798 - Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery N/A
Not yet recruiting NCT05035069 - Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR Phase 4
Completed NCT03861364 - Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose. Phase 4
Completed NCT02711280 - The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children N/A
Completed NCT01199471 - Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane N/A
Completed NCT00917033 - Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy Phase 4
Completed NCT00391885 - Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy Phase 4
Completed NCT00552617 - A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) Phase 2
Completed NCT03705026 - Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population
Completed NCT00552929 - A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974) Phase 2
Completed NCT00475215 - Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Phase 3
Completed NCT00298831 - Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) Phase 3
Recruiting NCT03943745 - EEG Changes During Induction of Propofol Anesthesia
Completed NCT03697642 - Nasopharyngeal Airway Guide Nasogastric Tube Placement N/A
Completed NCT04595591 - Observation of Propofol Titration at Different Speeds N/A
Not yet recruiting NCT05841316 - The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
Completed NCT04532502 - Impact of Anesthetic Environment the Sex Ratio of the Children of Female Assistants
Completed NCT03330236 - EEG - Guided Anesthetic Care and Postoperative Delirium N/A
Recruiting NCT06205212 - High-flow Nasal Oxygenation During Preoxygenation and Atelectasis N/A
Completed NCT00379613 - Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) Phase 2